SG Americas Securities LLC decreased its stake in shares of Novartis AG (NYSE:NVS – Free Report) by 51.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,348 shares of the company’s stock after selling 10,948 shares during the quarter. SG Americas Securities LLC’s holdings in Novartis were worth $1,007,000 as of its most recent SEC filing.
A number of other hedge funds also recently bought and sold shares of NVS. Steigerwald Gordon & Koch Inc. lifted its position in shares of Novartis by 4.8% during the 3rd quarter. Steigerwald Gordon & Koch Inc. now owns 2,091 shares of the company’s stock worth $241,000 after buying an additional 95 shares during the last quarter. Centaurus Financial Inc. lifted its position in Novartis by 1.7% in the third quarter. Centaurus Financial Inc. now owns 5,728 shares of the company’s stock valued at $659,000 after acquiring an additional 98 shares during the last quarter. FLC Capital Advisors lifted its position in Novartis by 4.4% in the third quarter. FLC Capital Advisors now owns 2,366 shares of the company’s stock valued at $272,000 after acquiring an additional 100 shares during the last quarter. Clear Harbor Asset Management LLC boosted its stake in Novartis by 2.3% in the third quarter. Clear Harbor Asset Management LLC now owns 4,423 shares of the company’s stock valued at $509,000 after acquiring an additional 100 shares in the last quarter. Finally, Allen Wealth Management LLC increased its position in shares of Novartis by 1.8% during the third quarter. Allen Wealth Management LLC now owns 5,788 shares of the company’s stock worth $666,000 after purchasing an additional 100 shares in the last quarter. Institutional investors and hedge funds own 13.12% of the company’s stock.
Wall Street Analyst Weigh In
NVS has been the topic of a number of recent research reports. HSBC lowered shares of Novartis from a “hold” rating to a “reduce” rating in a research note on Wednesday, December 4th. BMO Capital Markets boosted their price target on Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a research report on Wednesday, October 30th. Finally, Erste Group Bank reaffirmed a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. Two investment analysts have rated the stock with a sell rating and six have issued a hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $123.38.
Novartis Stock Performance
Shares of NVS opened at $101.85 on Wednesday. The firm has a 50-day moving average price of $100.10 and a 200 day moving average price of $108.64. The firm has a market capitalization of $208.19 billion, a PE ratio of 11.83, a P/E/G ratio of 1.42 and a beta of 0.57. Novartis AG has a 52-week low of $92.35 and a 52-week high of $120.92. The company has a quick ratio of 0.90, a current ratio of 1.11 and a debt-to-equity ratio of 0.55.
Novartis (NYSE:NVS – Get Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $2.06 earnings per share for the quarter, topping the consensus estimate of $1.94 by $0.12. Novartis had a net margin of 35.96% and a return on equity of 34.80%. The firm had revenue of $12.82 billion for the quarter, compared to analysts’ expectations of $12.62 billion. During the same period in the previous year, the company posted $1.74 EPS. On average, sell-side analysts anticipate that Novartis AG will post 7.62 earnings per share for the current fiscal year.
About Novartis
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Further Reading
- Five stocks we like better than Novartis
- How to Calculate Return on Investment (ROI)
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- Low PE Growth Stocks: Unlocking Investment Opportunities
- What Does the Future Hold for Eli Lilly?
- Investing in Construction Stocks
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.